INT56219

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.53
First Reported 1994
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 16
Total Number 16
Disease Relevance 5.59
Pain Relevance 1.23

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (KDM5D) nucleus (KDM5D) intracellular (KDM5D)
DNA binding (KDM5D) molecular_function (KDM5D) cellular_component (KDM5D)
Anatomy Link Frequency
elbow joint 1
KDM5D (Homo sapiens)
Pain Link Frequency Relevance Heat
visual analogue scale 33 99.80 Very High Very High Very High
Inflammation 12 98.62 Very High Very High Very High
Pain 101 95.42 Very High Very High Very High
abdominal pain 2 89.12 High High
depression 62 67.76 Quite High
psoriasis 22 54.92 Quite High
methotrexate 1 47.60 Quite Low
anesthesia 2 5.00 Very Low Very Low Very Low
alcohol 2 5.00 Very Low Very Low Very Low
positron emission tomography 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Age-related Macular Degeneration 15 99.72 Very High Very High Very High
Leukocytosis 2 99.72 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 156 98.92 Very High Very High Very High
INFLAMMATION 8 98.62 Very High Very High Very High
Dislocations 42 98.58 Very High Very High Very High
Disease 275 98.54 Very High Very High Very High
Pain 101 95.42 Very High Very High Very High
Abdominal Pain 2 89.12 High High
Reprotox - General 3 2 88.24 High High
Infection 30 78.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
During genital inflammation, whether postoperative or postinfectious, leukocytosis and elevated levels of HYA and myeloperoxidase were found in the PF.
Gene_expression (levels) of HYA associated with inflammation and leukocytosis
1) Confidence 0.53 Published 1994 Journal Inflammation Section Abstract Doc Link 8206644 Disease Relevance 0.53 Pain Relevance 0.26
Thirty-eight occupational therapists, 30 physiotherapists and 47 speech pathologists were trained at 13 participating facilities to collect AusTOMs data, and to present the EQ-5D for clients to complete.
Gene_expression (present) of EQ-5D
2) Confidence 0.45 Published 2004 Journal Health Qual Life Outcomes Section Body Doc Link PMC543469 Disease Relevance 0.12 Pain Relevance 0.12
In view of the lack of therapist-administered tool suitable to validate the AusTOMs against, and given the time administration advantages of the use of the EQ-5D which were significant to the success of this research program, the EQ-5D was selected for inclusion in the present study.
Gene_expression (selected) of EQ-5D
3) Confidence 0.45 Published 2004 Journal Health Qual Life Outcomes Section Body Doc Link PMC543469 Disease Relevance 0 Pain Relevance 0
This may be viewed as the main limitation in selecting the the EQ-5D for comparison with the AusTOMS.
Gene_expression (selecting) of EQ-5D
4) Confidence 0.45 Published 2004 Journal Health Qual Life Outcomes Section Body Doc Link PMC543469 Disease Relevance 0 Pain Relevance 0
During genital inflammation, whether post-operative or postinfectious, leukocytosis and elevated levels of HYA and myeloperoxidase were found in the PF.
Gene_expression (levels) of HYA associated with inflammation and leukocytosis
5) Confidence 0.43 Published 1994 Journal Inflammation Section Abstract Doc Link 8070899 Disease Relevance 0.53 Pain Relevance 0.26
Results indicated that the impact of age-related macular degeneration was not well reflected in the EQ-5D or SF-6D with mean utility values of 0.72 (standard deviation = 0.22) and 0.66 (standard deviation = 0.14) respectively.
Neg (not) Gene_expression (reflected) of EQ-5D associated with age-related macular degeneration
6) Confidence 0.29 Published 2010 Journal Health Qual Life Outcomes Section Body Doc Link PMC2844366 Disease Relevance 0.66 Pain Relevance 0
Although no disease-specific utilities were identified, the following generic measures were used in both indications: EQ-5D, 15D, SF-6D, and the HUI (versions 2 and 3).
Gene_expression (used) of EQ-5D associated with disease
7) Confidence 0.29 Published 2010 Journal Health Qual Life Outcomes Section Body Doc Link PMC2844366 Disease Relevance 0.83 Pain Relevance 0
The EQ-5D produces three types of data for each respondent: (1) a description of the extent of the problem along five health dimensions; (2) a population-weighted health index; and (3) a self-rated assessment of health status using a visual analog scale (VAS) (Kind 1996).
Gene_expression (produces) of EQ-5D
8) Confidence 0.27 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936269 Disease Relevance 0.33 Pain Relevance 0.13
However on closer reflection utility results varied, with EQ-5D scores being significantly higher in healthy populations, and SF-6D scores being significantly higher in disease samples, thus pointing to differences in scaling and a lack of calibration between utility measures [71].
Gene_expression (scores) of EQ-5D associated with disease
9) Confidence 0.25 Published 2010 Journal Health Qual Life Outcomes Section Body Doc Link PMC2844366 Disease Relevance 0.57 Pain Relevance 0
Bland-Altman plots with limits of agreement [21] were also prepared (Figure 1) to visually represent agreement levels between conventional change and patient perceived change as well as for conventional change and patient perceived change adjusted for recall bias (for EQ-5D utility and VAS).
Gene_expression (utility) of EQ-5D associated with visual analogue scale
10) Confidence 0.18 Published 2010 Journal Health Qual Life Outcomes Section Body Doc Link PMC2912788 Disease Relevance 0 Pain Relevance 0.09
Change scores were calculated for both EQ-5D utility and VAS.
Gene_expression (utility) of EQ-5D associated with visual analogue scale
11) Confidence 0.18 Published 2010 Journal Health Qual Life Outcomes Section Body Doc Link PMC2912788 Disease Relevance 0 Pain Relevance 0.05
The secondary outcome measures are:

• Functional outcome (Mayo Elbow Performance Index and Oxford Elbow Score) • Pain level at both sides (VAS) • Range of Motion of the elbow joint at both sides • Rate of secondary interventions • Rate of complications (secondary dislocation, instability, relaxation) • Health-related quality of life: SF-36 and EQ-5D • Radiographic appearance of elbow joint (degenerative changes and heterotopic ossifications) • Cost • Cost-effectiveness

Gene_expression (appearance) of EQ-5D in elbow joint associated with pain and dislocations
12) Confidence 0.09 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2994812 Disease Relevance 0.28 Pain Relevance 0.18
Median EQ-5D VAS scores were 64.5, 70, and 75 for CD4 < 50, 50–199, ?
Gene_expression (scores) of EQ-5D
13) Confidence 0.04 Published 2007 Journal Health Qual Life Outcomes Section Body Doc Link PMC1796859 Disease Relevance 0.22 Pain Relevance 0
In a cross sectional study of a sample of HIV-infected patients, Delate and Coons demonstrated that EQ-5D health index scores and VAS discriminated between patients with CD4 ?
Gene_expression (discriminated) of EQ-5D associated with acquired immune deficiency syndrome or hiv infection
14) Confidence 0.04 Published 2007 Journal Health Qual Life Outcomes Section Body Doc Link PMC1796859 Disease Relevance 1.09 Pain Relevance 0.05
A predicted VAS (pVAS) was estimated in a random effects linear regression model[6] by regressing the five EQ-5D health states on VAS using indicator coding of the health states.
Gene_expression (regressing) of EQ-5D
15) Confidence 0.04 Published 2007 Journal Health Qual Life Outcomes Section Body Doc Link PMC1796859 Disease Relevance 0.26 Pain Relevance 0
This could be due to the fact that HRQoL in rural Vietnam reaches beyond recently set EQ-5D levels in these developed countries.
Gene_expression (levels) of EQ-5D
16) Confidence 0.03 Published 2010 Journal BMC Public Health Section Body Doc Link PMC2944376 Disease Relevance 0.17 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox